T he presence of antimitochondrial autoantibodies (AMA) is widely utilized for the diagnosis of primary biliary cholangitis (PBC). (1, 2) AMA can be detected before the appearance of disease symptoms. Although AMA is not associated with disease severity/prognosis, (3) its presence before the development of liver pathology raises the possibility that it may contain information about early events in PBC. AMA recognize a unique conformational epitope within the inner lipoyl domain (ILD) of PDC-E2 (amino acid [aa] residue 177-314), (2) and we have hypothesized that the loss of tolerance to PDC-E2 is a result of chemical modification of this epitope following xenobiotic exposure. (4) In fact, quantitative structure-activity relationship analysis demonstrated that when the lipoyl domain of PDC-E2 is modified with specific synthetic lipoyl mimics, some of the ensuing structures are recognized by AMA-often at levels higher than native PDC-E2. (5) (6) (7) Furthermore, AMA can be induced in animals immunized with a lipoyl mimic xenobiotic conjugated with bovine serum albumin (BSA). (8, 9) Fine analysis of AMA specificity demonstrates that AMA-positive PBC sera contain subpopulations that recognize xenobiotic conjugated PDC-E2 ILD, native PDC-E2 peptide backbone, and also the xenobiotic itself. (4, 10) More interestingly, antibodies directed against xenobiotic conjugated PDC-E2 lipoyl domain are predominantly of the immunoglobulin (Ig) M isotype and are found in sera from early-stage PBC patients. (4, 10) These observations suggest that antibody specificity to xenobiotics may be footprints to the early events in loss of tolerance.
We have utilized a novel protein engineering approach using intein technology to generate a 138-residue PDC-E2 fragment by ligation of a recombinant peptide encoding residues 177-252 of human PDC-E2 (PDC-228) to a 62-aa peptide (PP) corresponding to residues 253-314 of the ILD of human PDC-E2, of which the sole lysine residue of the PP was left unconjugated (control) or conjugated with either lipoic acid (LA) or 2-octynoic acid (2OA). This moiety, 2OA, was selected because AMA contain a population of antibodies that recognize the 2OA-PDC-E2 peptide that are demonstrably distinct from antibodies in the same AMA population that recognize the naturally lipoylated form of PDC-E2. These findings imply that when 2OA modifies the PDC-E2 peptide, it acquires a molecular structure distinct from the naturally lipoylated form of the PDC-E2 peptide. The importance of our focus on 2OA is highlighted by the finding that 2OA is widely used in human products, such as artificial flavorings, perfumes, soaps, detergents, lipsticks, toilet waters, facial creams, and perfumed cosmetics. (5) We set out to determine whether xenobiotic modification of the PDC-E2 lipoyl domain also leads to conformational changes to the PDC-E2 peptide backbone. The effect of the hapten conjugation on PDC-E2 structure was analyzed by electron paramagnetic resonance (EPR) spectroscopy, enzyme-linked immunosorbent assay (ELISA), inhibition ELISA, immunoblotting, and affinity antibody analysis. Our data indicate that 2OA-modified PDC-E2 exhibits a conformational change in the PDC-E2 ILD backbone, which is distinctly different from the native ILD of PDC-E2. Taken together, these observations provide key evidence for a chemical xenobiotic etiology of PBC.
Patients and Methods

SERUM SAMPLES
Serum samples from 128 patients with PBC, 37 patients with primary sclerosing cholangitis (PSC) and 52 healthy controls (HCs) were used in this study. The
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clinical diagnosis of all patients was verified using published criteria. (11) (12) (13) (14) This study was approved by the institutional review board of the University of California at Davis (Davis, CA).
CONSTRUCTION, EXPRESSION, AND PURIFICATION OF RECOMBINANT PDC-228
Recombinant PDC-228 was constructed in expression plasmid vector pTXB1 (New England Biolabs, Ipswich, MA USA). A 228-base-pair insert encoding for aa residues 177-252 of PDC-E2 was amplified using oligonucleotide primers and, ultimately, the PCR product purified. The double-digested PCR product and vector were finally purified and ligated and transformed into Escherichia coli T7 Express Competent cells. Plasmid DNA from transformed E. coli colonies were verified by nucleotide sequence determination. Recombinant peptide was purified from an expression clone of PDC-228 in E. coli DH5 alpha and concentrated by ultrafiltration and quantified before subsequent intein-mediated protein ligation (IPL).
PREPARATION OF THE ILD OF HUMAN PDC-E2 BY IPL
Because there are five lysine (Lys) residues (Lys177, Lys240, Lys241, Lys245, and Lys259) within the ILD of PDC-E2 (residues 177-314), we have utilized IPL to obtain conjugates of 2OA and LA specifically at Lys259, given that other lysine modifications on recombinant PDC-E2 (residues 177-314) would influence its molecular conformation. By using a novel ligation approach, we have circumvented this difficulty by incorporating PP (residues 253-314) with its single lysine (Lys259) conjugated with 2OA or LA chemically. Subsequently, it was ligated with the recombinant PDC-228 (residues 177-252), with its four native lysines unmodified. First, a 62-aa peptide encoding residues 253-314 from the ILD of human PDC-E2 was chemically synthesized (Genemed Synthesis, Inc. San Antonio, USA). This peptide contains a unique lysine residue for chemical conjugation of N-hydroxysuccinimide (NHS)-activated xenobiotics and two cysteine residues (positions 253 and 273) around the lipoyl lysine to facilitate subsequent EPR spectroscopy. PP, 2OA, and LA conjugated PP were subsequently ligated with a recombinant peptide encoding aa177-252 of human PDC-E2 (PDC-228) using ILP to generate a 138-residue protein fragment corresponding to the residues 177-314 of PDC-E2. LA AND 2OA  TO THE 62-RESIDUE ILD  PEPTIDE OF PDC-E2 AND  LIGATION OF PDC-228 WITH  CONJUGATED OR  UNCONJUGATED PP BY IPL NHS esters of LA and 2OA were prepared (4) and conjugated to the PP Lys259 and the protein concentrations of PP conjugated with 2OA (2OA-PP) and PP conjugated with LA (LA-PP) and thence quantified. Ligation of the PP peptide with the PDC-228 fragment was carried out by IPL to generate the PPL protein construct. The ligation for 2OA-PP and PDC-228 (2OA-PPL) was performed in a mixture consisting of 0.25 mg/mL of PDC-228, 0.4 mg/mL of 2OA-PP, and 100 mM of 2-mercaptoethanesulfonic acid (MESNA) (SigmaAldrich, St Louis, MO USA) in the presence of 0.1 M of Tris-HCl (pH, 8.5) at 48C for 5 days (Fig. 1) .
CONJUGATION OF
SPIN LABELING AND EPR SPECTROSCOPY ANALYSIS
We engineered the PDC-E2 ILD to contain two spin labels, given that observation of either a change in spin-label dynamics or distance between the labels can serve as a reporter for the loop structure. Because there was already a native cysteine at position 273 within this loop structure, position alanine (Ala) 253 was substituted with cysteine (Cys) to create a second site for targeting the methanethiosulfonate (MTS) spin label (MTSL). Detection of distances by measuring the dipolar interaction of spin labels provides the ability to probe specific structural features of proteins in solution. (15) Cys 253 and 273 of PP, 2OA-PP and LA-PP, PPL, LA-PPL, and 2OA-PPL were spin labeled using the thio-specific nitroxide spin label (MTSL;
[1-oxyl-2,2,5,5-tetramethylpyrroline-3-methyl] MTS), a gift from Prof. Kalman Hideg, P ecs University (P ecs, Hungary). Unreacted spin label was removed by gel filtration chromatography. EPR measurements were conducted on a JEOL FA-100 EPR spectrometer (JOEL USA, Inc. Peabody, MA, USA) using a TE 011 cavity. Aliquots (25 lL) of purified peptide or ligated protein at described concentrations were loaded into a quartz flat cell, and spectra were collected at room temperature (20-228C) with three average scans each with 2 minutes of scan time and a 100-G sweep width at a microwave power of 3 mW. When included in the analyses, sample was incubated with Ficoll-70 (350 g/L final concentration) for 1 hour. Rate of spin label rotational reorientation was calculated from the EPR line width and line height ratios (16) using the following equation (Equation (1) To determine whether the three intein-mediated ligated proteins (PPL, LA-PPL, and 2OA-PPL) still retained their AMA reactivity, they were analyzed by immunoblotting. A recombinant PDC-E2 peptide (rPDC-E2) containing the same backbone aa (177-314aa) (17) as the three ligated proteins was prepared and used as the positive control. Immunoreactivity was detected using horseradish-peroxidase-conjugated antihuman Ig (IgG, IgM, and IgA) (Invitrogen, Carlsbad, CA, USA) as secondary (1:30,000 dilution) and chemiluminescence. ELISA plates were coated with either rPDC-E2, or LA-PPL, or 2OA-BSA and BSA (10 lg/well in carbonate coating buffer) at 4 o C overnight, then blocked with 3% skim milk in PBC using our standard protocol with positive/negative controls. (18) An inhibition ELISA was set up to determine whether a subpopulation of AMA specifically recognizes the molecular conformational change in 2OA-PPL peptide backbone induced by 2OA conjugation. A nested set of 30 sera, including 15 PBC in stages I Lysates of E. coli expressing PDC-228 recombinant protein is mixed with chitin resin. PDC-228 is attached by the intein-chitin binding domain (CBD) by peptide linkage between leucine (Leu) residue on the C-terminus of PDC-228 and Cys residue on the N-terminus of intein with the chitin resin for affinity purification of PDC-228. MESNA is used as the thiol reagent to induce intein-mediated cleavage on the column when the chemical bond between the Leu and Cys residue undergoes a spontaneous N-S acyl shift, which produces a C-terminal thioester of PDC-228 (step A and step B). Thereafter, the C-terminus of PDC-228 is attacked by the Cys on the N-terminal of PP or xenobiotic-modified PP and can then be covalently ligated with each other (steps C and D). Finally, a native peptide bond between the PDC-228 and PP or xenobiotic-modified PP is generated by the spontaneous S-N acyl shift, and the ligated product 2OA-PPL is obtained (step E). R 5 2OA or LA. Abbreviation: LD, lipoyl domain.
and II and 15 in stages III and stage IV that have been previously shown to react with both LA-PPL and 2OA-PPL, but not BSA, were chosen. Individual samples were serially diluted and incubated with 1 mL of cyanogen bromide (CNBr)-activated Sepharose beads (GE Healthcare, Uppsala, Sweden) conjugated with 100 ug of either 2OA-PPL, LA-PPL, 2OA-BSA, LA-PPL plus 2OA-BSA, BSA, or human albumin (ALB) (Sigma-Aldrich, St Louis, MO USA) at 4 o C overnight on a rocker. Absorbed sera were analyzed by ELISA to ensure complete absorption. Reactivity of the absorbed and unabsorbed sera against 2OA-PPL, LA-PPL, and 2OA-BSA were determined by ELISA.
PREPARATION OF AFFINITY-PURIFIED ANTIBODIES
To further determine the specificities of the autoantibody population against 2OA-PPL, LA-PPL, and 2OA, affinity-purified antibodies from 6 of the 13 PBC sera in group A, identified by inhibition ELISA, were prepared. Briefly, LA-PPL, 2OA-BSA, or 2OA-PPL was separately conjugated to CNBr-activated Sepharose beads. Individual selected serum samples were diluted 20 times with 10 mM of Tris-HCl (pH, 7.5) and filtered through a 0.45-lm filter. Diluted serum was first passed through the CNBr-2OA-BSA column three times, washed, and the bound anti-2OA antibodies were eluted off with 100 mM of glycine (Sigma-Aldrich, St Louis, MO USA) (pH, 2.5) and neutralized immediately with 1 M of Tris-HCl (pH, 8.0). The flow-through was then passed through the CNBr-LA-PPL column, and the anti-LA-PPL antibody was eluted under similar conditions. Thereafter, the flow-through fraction of CNBr-LA-PPL column was repassed through refreshed CNBr-LA-PPL and CNBr-2OA-BSA columns three to five times to remove the antibodies against LA-PPL and 2OA-BSA until its reactivity against LA-PPL and 2OA-BSA could not be detected by ELISA. This final flowthrough was then passed through the CNBr-2OA-PPL column, and the remaining bound antibody was eluted with glycine elution buffer and neutralized using Tris-HCl (pH, 8.0).
EPITOPE SPECIFICITY AND ISOTYPE DETERMINATION OF AFFINITY-PURIFIED ANTIBODIES
To determine the epitope specificity of the affinitypurified antibody, in particular, if there is an antibody population that recognizes only 2OA-PPL, but not 2OA-BSA, PDC-E2, LA-PPL, and PPL, the affinity-purified fractions were analyzed by immunoblotting against 2OA-PPL, 2OA-BSA, PDC-E2, LA-PPL, and PPL. Reactivity was determined using antihuman Ig (IgG, IgM, and IgA) antibodies as secondary antibody. (4) To further determine the Ig isotype of affinity-purified antibodies, 96-well ELISA plates were coated with either 2OA-PPL, 2OA-BSA, or LA-PPL and incubated with affinity-purified fractions, antibodies against 2OA-BSA, or LA-PPL, respectively.
STATISTICAL ANALYSIS
Mean and SD were used to describe and calculate the results from ELISA and inhibition ELISA. A two-tailed unpaired t test with Welch's correction was conducted to analyze the differences of antibodies reactivity against the modified proteins and the ratio of IgG/IgM. Enumeration data were analyzed by Fisher's exact test.
Results
PPL, LA-PPL, AND 2OA-PPL LIGATION PRODUCTS ARE REACTIVE WITH AMA
The ILD of PDC-E2 encompasses residues spanning positions 250-314. To generate a PDC protein construct that would facilitate modifications of Lys259, we used intein-mediated ligation to join the 76-residue PDC-228 peptide with the 62-residue ILD peptide (PP, LA-PP, or 2OA-PP) to generate PPL and 2OA-PPL ( Fig. 2A) . We tested the resulting ligation products for recognition by immunoblotting with AMA-positive sera. AMA readily react with PPL, LA-PPL, and 2OA-PPL, providing reagents that appear as immunological mimics of PDC-E2 (Fig.  2B) . Next, we analyzed the specificity of serum samples from patients with PBC, PSC, and HC against LA-PPL and for purposes of peptide control 2OA-BSA by ELISA. We also screened aliquots of the same sera against rPDC-E2 and BSA that served as positive and negative controls. As expected, PBC sera reacted to rPDC-E2, LA-PPL, and 2OA-BSA, but not BSA. None of the sera from PSC and HC reacted to either rPDC-E2, LA-PPL, 2OA-BSA, or BSA (Fig. 3) . In the HC group, the mean reactivity (optical density [OD] 6 2 SDs) of the sera against rPDC-E2, LA-PPL, and 2OA-BSA were 0.1635, 0.1609, and 0.0877, respectively. Using these OD readings as the positive or negative cut-off values of autoantibody to the corresponding proteins, sera from PBC demonstrate rates of reactivity against rPDC-E2, LA-PPL, and 2OA-BSA of 92.19% (118 of 128), 94.53% (121 of 128), and 46.88% (61 of 128), respectively.
IMMUNOABSORPTION ANALYSIS IDENTIFIED AN AMA SUBPOPULATION SPECIFIC TO 2OA-PPL
To determine whether there is a subpopulation of antibodies with specificity for 2OA-PPL, but not for LA-PPL and 2OA, in PBC patients, sera from 30 PBC patients, which have been previously determined to recognize both LA-PPL and 2OA-BSA, were absorbed with either 2OA-PPL, LA-PPL, or 2OA-BSA individually and also a mixture containing both LA-PPL and 2OA-BSA. As negative controls, serum samples were also absorbed with BSA and ALB. The absorbed serum samples were analyzed for their reactivity to 2OA-PPL, LA-PPL, and 2OA-BSA at 1:250, 1:500, 1:1,000, and 1: 2,000 sera dilution (Fig.  4) by ELISA.
All serum samples absorbed with 2OA-PPL lost almost all of their reactivity to 2OA-PPL. Serum samples absorbed with either ALB or BSA or 2OA-BSA retained almost 100% of their reactivity to 2OA-PPL (Fig. 4A,B) . The pattern of reactivity of sera following absorption with a mixture of LA-PPL12OA-BSA led us to divide the sera into two groups: group A sera being those sera that following absorption with LA-PPL12-OA-BSA still reacted with 2AO-PPL and group B that failed to show residual activity against 2AO-PPL. Thirteen of 30 serum samples were classified as belonging to group A and the remaining 17 of 30 to group B (Fig. 6A,B) . We interpret these findings as evidence for the presence of antibodies not only to LA-PPL and 2-OA, but that a significant fraction of PBC sera (43.3%) in addition contain antibodies with specificity for 2OA-PPL. 5) ; LA-PPL (lanes 2 and 6); 2OA-PPL (lanes 3 and 7); and rPEC-E2 (lanes 4 and 8) . Note that all the three ligations and rPDC-E2 reacted with AMA (1) serum. Serum samples from AMA-negative PBC patients and HCs do not react. Abbreviation: SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis.
FIG. 3.
Ig reactivity of serum samples from patients with PBC (n 5 128) against rPDC-E2, LA-PPL, 2OA-BSA, and BSA by ELISA. Patients with PSC (n537) and HCs (n552) were studied in parallel. Note that the reactivity of antibody against rPDC-E2, LA-PPL, and 2OA-BSA was detected only in PBC, but not in PSC, patients and HCs. Data are presented as mean 6 SD. Asterisks (****) and rhombus (᭜᭜᭜᭜) indicate significant differences (P < 0.0001, two-tailed unpaired t test with Welch's correction).
FIG. 4.
Inhibition ELISA of PBC serum against 2OA-PPL, LA-PPL, and 2OA-BSA. Serum from 30 AMA-positive PBC sera were individually absorbed with 2OA-PPL, LA-PPL, and 2OA-BSA and dually absorbed with the combination of LA-PPL and 2OA-BSA. Serum samples absorbed separately by BSA and ALB were included as controls. Based on the reactivity pattern of the absorbed serum samples to 2OA-PPL, we noted that the 30 selected PBC samples with both antibodies to LA-PPL and 2OA-BSA could be divided into either group A or group B. In group A (n 5 13), serum samples absorbed with the combination of LA-PPL and 2OA-BSA could retain a significant higher reactivity to 2OA-PPL, whereas in group B (n 5 17) serum samples absorbed with the combination of LA-PPL and 2OA-BSA did not show any difference in their reactivity to 2OA-PPL. These data suggested the possibility that a subpopulation of AMA with specificity to 2OA-PPL, but not LA-PPL and 2OA, existed in the group A serum samples (A,B). The serum samples absorbed by LA-PPL in group A had distinctively higher reactivity than those absorbed by the combined adsorption, whereas this difference in reactivity to 2OA-PPL was not significant in group B, which indirectly supported the existence of an AMA subpopulation that recognizes 2OA-PPL, but not LA-PPL and 2OA (A,B). The serum samples absorbed with 2OA-PPL in both groups remained reactive to LA-PPL (C,D). However, when they were absorbed by any proteins containing 2OA-PPL, their reactivity to 2OA-BSA was similar to serum samples absorbed by 2OA-BSA (E,F). Moreover, serum reactivity to 2OA-BSA was not affected by LA-PPL absorption in both groups (Fig. 5E,F) . Data are presented as mean 6 SEM. The twotailed unpaired t test with Welch's correction was used to analyze all the differences between absorbed serum reactivity. *Statistically significant difference compared with 2OA-PPL absorption (*P < 0.05; **P < 0.01; ****P < 0.001).
# Statistically significant difference compared with the combined absorption of LA-PPL and 2OA-BSA ( # P < 0.05). ' Statistically significant difference compared with the LA-PPL absorption ( ' P < 0.05; '' P < 0.01).
When absorbed sera were assayed for their reactivity to LA-PPL (Fig. 4C,D) , all sera absorbed with LA-PPL lost nearly all of their reactivity to LA-PPL. Serum samples absorbed with either ALB or BSA or 2OA-BSA retained almost 100% of their reactivity to 2LA-PPL. Sera absorbed with a combination of 2OA-BSA and LA-PPL lost all their reactivity to LA-PPL. Interestingly, sera absorbed with 2OA-PPL lost most, but not all, of their reactivity to LA-PPL, suggesting that there is another subpopulation of antibodies that only recognize LA-PPL. When absorbed sera were assayed for their reactivity to 2OA-BSA (Fig. 4E,F) , samples absorbed with either ALB or BSA retained almost 100% of their reactivity to 2OA-BSA. Sera samples absorbed with LA-PPL also retained almost 100% reactivity to 2OA-BSA, indicating the presence of 2OA-specific antibodies in PBC. Sera samples absorbed with 2OA-BSA, 2OA-PPL, and a mixture of 2OA-BSA plus LA-PPL lost almost all of their reactivity to 2OA-BSA.
AFFINITY PURIFIED ANTIBODY TO THE 2OA-PPL ALTERED PDC-E2 BACKBONE DO NOT RECOGNIZE 2OA-BSA AND LA-PPL AND ARE PREDOMINANTLY IgM
We have identified a unique subpopulation of AMA that specifically recognizes the altered molecular structural on the backbone of 2OA-PPL caused by 2OA conjugation. Immunoblotting showed that the purified subpopulation of antibodies against 2OA-PPL only recognized 2OA-PPL, but not LA-PPL, 2OA-BSA, PPL, or rPDC-E2 (Fig. 5A ). More important, IgG/ IgM ratio among the antibodies against LA-PPL, 2OA-BSA, and 2OA-PPL were significantly different. The predominant antibody to LA-PPL was composed of IgG. In contrast, the antibody with specificity for 2OA-PPL and the antibody against 2OA-BSA were mainly IgM (Fig. 5B,C) .
AMA SUBPOPULATION SPECIFIC TO 2OA-PPL STRUCTURE INDUCED BY 2OA CONJUGATION ARE PRESENT PREDOMINANTLY IN EARLY STAGES OF PBC
Next, we compared the reactivity of sera from the 13 patients with antibody with specificity for 2OA-PPL in group A and sera from the remaining 17 patients in group B with respect to their age, sex ratio, and stage of disease. There are no significant differences between the two groups in age and sex ratio. However, a high frequency (10 of 13) of samples from group A belonged to patients with early-stage PBC disease (66.67%), and a minor subset (3 of 13) belonged to patients in late stage (P 5 0.025; Supporting Table  S2 ).
EPR ANALYSIS INDICATED A MARKED STRUCTURAL CHANGE IN 2OA-PPL
We set out to determine whether conjugation of 2OA to the ILD may result in unsuspected structural alterations and creation of a neoepitope. There is a fair degree of chemical similarity between 2-OA and LA, so this would be somewhat surprising. The lysine at position 259 is the residue at which lipoyl addition occurs in native PDC-E2 ILD. Molecular structure analysis of this lipoylated molecule shows that it folds as a loop. (19) To determine how the structure of this region relates to antigenicity, we analyzed the dynamics of PPL, LA-PPL, and 2OA-PPL using EPR spectroscopy of spin labels attached simultaneously at positions 253 and 273. Both positions reacted with the thio-specific nitroxide spin label, MTSL, and, additionally, we made a construct with Ala substituted for Cys at position 253.
The EPR spectra of the spin-labeled PP, with and without ligation to PDC-228, are shown in Fig. 6 . Samples were measured at 1 mg/mL of protein, as determined by BCA protein assay, and were plotted normalized to the same molar concentration of each polypeptide. Because of the relatively small size of both the free and ligated ILD peptides (6.8 and 14.7 kD, respectively), a fast rate of global tumbling in solution is expected to significantly contribute to the motional averaging of the EPR spectra. Thus, samples were examined under high viscosity (30% Ficoll) to decrease the rate of global tumbling. EPR spectra of the ILD peptides in Ficoll contain narrow lines and are largely isotropic, indicating a high degree of dynamic disorder. An empirical estimation of the rates of motion is given in Supporting Table S1 .
The sharp EPR spectrum of the ILD peptide (PP) reflects a high level of motional freedom arising from both spin labels (Fig. 6A) . Following ligation with the PDC-228 peptide, intensity of EPR spectrum decreases significantly. However, the spectral line shape does not display features of a strongly immobilized label, indicating that the spin labels remain in a relatively dynamic environment following ligation. Given the lack of spectral change, the broadening can largely be attributed to the rapid modulation of the dipolar interaction between labels. (20) Magnetic interaction between spins becomes strong enough to affect the spectrum when the nitroxides are within 2 nm of one another. (21) Thus, PDC228 facilitates the formation of the ILD loop conformation, placing positions 253 and 273 within a close proximity of one another.
When the PP and PPL were ligated with LA and 2OA, the results obtained show dramatically different outcomes with respect to a dipolar interaction between the spin labels attached at positions 253 and 273. Thus, whereas the sample with LA displays a level of spectral broadening similar to the unmodified protein (Fig. 6B) , lipoylation with 2OA does not result in a broadened EPR spectrum (Fig. 6C) . This indicates that the loop structure of the lipoyl domain remains intact with LA modification, but, upon modification with 2OA, became incapable of positioning the spins within a close (<2 nm) proximity. A comparison of the ligated samples with and without lipoylation is shown in Fig. 7 . The correlation time of the faster motion within the ensemble can be estimated from the empirical relation given in Equation (1) (Patients and Methods). The estimated correlation times of the spectra in Fig. 6A -C are given in Supporting Table  S1 . Following ligation, the estimated rate of motion of the labels in lipoylated samples are approximately 50% faster, suggesting that although ligation with LA has . This population of affinity-purified antibodies was analyzed for their isotype against 2OA-PPL using anti-IgM and anti-IgG as secondary antibodies. Reactivity of affinitypurified antibodies to LA-PPL and 2OA-BSA against LA-PPL and 2OA-BSA was studied in parallel. IgG was the major isotype of antibody to LA-PPL, whereas IgM was the predominant isotype of antibodies to 2OA-PPL and 2OA-BSA (B). Further analysis indicated that the differences of IgG/IgM ratios among the three antibodies were statistically significant (C): IgG/IgM ratio for antibody to LA-PPL was the highest and more than 1 whereas the ratio for antibody against 2OA-BSA was the lowest. The ratio of the antibody to 2OA-PPL was between that of antibodies to LA-PPL and 2OA-BSA, but was significantly different from both of them. Data are presented as mean 6 SD. *Significant difference (****P < 0.001, two-tailed unpaired t test with Welch's correction). some dynamic effects on the ILD loop, the effects are not substantial enough to disrupt its hairpin structure.
AFFINITY-PURIFIED AMA ALTERS THE EPR SPECTRUM OF 2OA-PPL, BUT NOT LA-PPL
Because EPR analysis of spin labels within the ILD loop can distinguish conformational states induced by either LA or 2OA, we then measured the response of each sample to the presence of AMA. The effect of AMA on the EPR spectra of spin-labeled ILD protein is shown in Fig. 8 . Whereas the addition of an aliquot of antibody with specificity for 2OA-PPL (1-mg/mL final concentration) from AMA-positive sera to 1 mg/mL of the protein construct did not affect the EPR spectrum of LA-PPL, the addition of an aliquot of the same antibody to 2OA-PPL results in the appearance of a spin-exchangebroadened component to the EPR spectrum (Fig. 8B ).
Discussion
Accumulating evidence implicates both genetic susceptibility (22) (23) (24) (25) (26) (27) and environmental insults (28) (29) (30) as contributing to the etiology of PBC. However the underlying mechanism leading to loss of self-tolerance remains an enigma. This is an issue throughout autoimmunity, often called "searching for the holy grail." (2, (31) (32) (33) (34) (35) (36) Using high-resolution structural analysis and modeling studies on the lipoyl domains of PDC-E2, LA is prominently displayed on the outer surface of PDC-E2 and rotates by means of a "swinging arm" with respect to the bulk of the molecule. (19) In PDC-E2, LA is covalently attached with the group of lysine (Lys259) by an amide bond. LA contains two sulfur atoms at C6 and C8, which are connected by a disulfide bond. During this biochemical process, the LA dithionate ring is susceptible to xenobiotic modifications, particularly in the biliary tract. Lipoate-protein ligase catalyzes the covalent attachment of LA to Lys259 on the PDC-E2 lipoyl domain in a two-step reaction, during which a variety of other carboxylic acids, including those without the dithiolane ring (such as some xenobiotic chemicals), could also be transferred to Lys259. (37, 38) In previous studies, we demonstrated that when PDC-E2 Lys259 was chemically conjugated with chemicals with similar molecular structures to LA, immune self-tolerance to PDC-E2 could be broken by cross-reactive immune responses against the LA. Such similar chemicals included 2OA. (5) However, the structural effect of xenobiotic conjugation at Lys259 on the PDC-PP peptide backbone and the immunological consequences of such conformational alterations were unknown. (8, 39, 40) 2-OA methyl esters are widely used in cosmetics, lipstick, chewing gums, and foods additives. (41) Our intein-mediated ligation approach not only facilitates the targeting of the 2OA and LA conjugations at Lys259, but provides a method to label the protein construct by site-directed labeling of Cys in the PP peptide. We engineered the PP to contain an additional Cys residue, by substituting Ala253 with Cys. Thus, the ligated PP peptides contained 2 Cys residues for labeling (position 253 and the native Cys273). These thiols allow for specific attachment of the MTS spin labels and subsequent EPR analysis to probe the structural consequences of conjugation with LA and the xenobiotic 2OA. Two spin labels within the ILD is advantageous given that the observation of either a change in spin-label dynamics or distance between the labels can serve as a reporter for the loop structure. This reflects a novel application of IPL for targeting of lipoylation and the incorporation of spin labels into a protein.
It is important to demonstrate that PPL, LA-PPL, and 2OA-PPL are each immune-reactive to AMA and this was shown by immunoblotting (Fig. 2) . This is of significance because they were all ligated by intein chemistry, residue Ala253 of PDC-E2 was substituted by Cys, and Lys259 was also chemically distinct from one another, with or without hapten conjugation (Fig.  2B) . Thus, AMA reactivity to PDC-E2 was directed to the ILD of PDC-E2, which could be in either native or modified form. EPR analysis of the spinlabeled peptide constructs was then carried out to probe the structural consequences of lipoylation with LA and the xenobiotic mimic 2-OA. The continuous wave approach applied in this study allows for the detection of spin pairs within 2 nm of each other. The results by EPR indicate that positions 253 and 273 in the ILD loop are on the order of 1.0-1.5 nm from each other, given the magnitude of broadening and the absence of spectral distortion attributed to spin exchange. The absence of broadening in protein lipoylated with 2OA demonstrates that positions 253 and 273 become separated by at least 2 nm, although these positions could, in theory, become separated by as much as 7 nm if the region were to fully extend.
From EPR, we noticed that there is a clear conformational difference between the 2OA-PPL and LA-PPL protein constructs. To investigate whether this change on 2OA-PPL could induce a specific subpopulation in AMA in PBC, or, in other words, whether this change induced any specific immune response in PBC, an inhibition ELISA was conducted (Fig. 4) .
FIG. 8.
Affinity-purified antibodies specific to 2OA-PPL from AMA-positive sera affects the EPR spectrum of the 2OA-PPL sample, but not the LA-PPL protein construct. The EPR spectra of LA-PPL and 2OA-PPL at 1 mg/mL are shown in (A) and (B), respectively (black traces). The red traces represent the EPR spectra following addition of the affinity antibody fraction from AMA-positive sera (final concentration of 1 mg/mL) to the LA-PPL (A) and 2OA-PPL (B) samples.
FIG. 7.
Comparison of EPR spectra for the PPL ligation products (PL, LA-PPL, and 2OA-PPL). All samples contained 30% Ficoll to diminish the contribution of global rotational diffusion to the EPR line shapes. All spectra are normalized to the same molar concentration of sample as determined by protein BCA assay.
The differences in inhibition ELISA imply the presence of an antibody subpopulation, which specifically recognized the epitopes on the backbone of PDC-E2 induced by 2OA modification. Furthermore, in both groups, sera absorbed by 2OA-BSA showed no obvious influence for its reactivity to 2OA-PPL, just as the sera absorbed by negative control BSA and ALB did (Fig. 4A,B) . Thus, it can be inferred that the antibody to the hapten 2OA plays a minor role in the reactivity of the sera against the backbone of PDC-E2. Similarly, the reactivity to 2OA and LA is also reflected in difference in reactivity to LA-PPL between the sera absorbed by 2OA-PPL and LA-PPL between groups A and B (Fig. 4C,D) . In both groups A and B, serum reactivity to 2OA-BSA was not influenced by LA-PPL adsorption (Fig. 4E,F) .
Based on inhibition ELISA data, affinity-purified antibody with specificity for 2OA-PPL, antibodies with specificity for LA-PPL, and antibody to hapten 2OA were separately obtained from six serum samples from group A. The antibodies against 2OA-PPL were further studied by immunoblotting in which this purified antibody could only recognize 2OA-PPL, but not 2OA-BSA, rPDC-E2, LA-PDC, and PPL (Fig. 5A) . Interestingly, the isotype of the three antibodies (antibody to 2OA-PPL, antibody to LA-PPL, and antibody to 2OA) were significantly different, though they were purified from the same PBC patients (Fig. 5B,C) . The antibody to 2OA was predominantly the IgM isotype, which was similar with the isotype of antibody to 6,8-bis(acetylthio) octanoic acid, one of the other xenobiotic lipoyl mimics. (4) The isotype of antibody to LA-PPL was predominantly IgG, as expected. More interestingly, the IgG/IgM ratio of the affinity antibody against 2OA-PPL was between that of antibody against LA-PPL and of antibody against 2OA (Fig. 5B,C) . It is reasonable that 2OA itself might trigger an immunological response to produce antibody against 2OA when 2OA is conjugated on Lys259 of PDC-E2 at the early induction phase. As the response progresses, autoantibody to the backbone of PDC-E2 are produced through epitopes spreading from 2OA to the PDC-E2 backbone. By the usual processes of somatic mutation and antibody affinity maturation, the isotype of autoantibody to the peptide backbone of PDC-E2 will switch from IgM to predominantly IgG. (42) We suggest that the coupling of a xenobiotic induces a conformational change that renders the ILD of PDC-E2 distinctly structurally altered to an extent where it is recognized as foreign, but with enough preserved structure such that induced antibodies cross-react to authentic LAconjugated PDC-E2. This occurs early in the process of tolerance breakdown, explaining why anti 2OA-ILD antibodies are enriched for IgM in early-stage disease. The natural history of PBC clearly begins with a break of tolerance, and the data herein emphasize these events. As the disease evolves, there will be additional effector pathways activated, which will include both innate and adaptive immunity. The relative roles of each of these pathways to both the initial loss of tolerance and then the subsequent continued adaptive response reflects what we have previously called a multiorchestrated immune response and may likely be different during the evolution of disease. (43) 
